Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 5/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740691 | 0.85 | GUSB (0.78) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL1084872 | 0.85 | GUSB (0.78) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL938466 | 0.83 | GUSB (0.55) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL295717 | 0.83 | GUSB (0.48) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL1623275 | 0.82 | TNKS (0.50) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL296062 | 0.82 | GUSB (0.70) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL939999 | 0.81 | CFTR (0.46) | GUSBCYP1A2NPC1RAB9A | |
| SCHEMBL182563 | 0.81 | TNKS (0.48) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL183430 | 0.80 | GUSB (0.59) | GUSBCYP1A1CYP1B1CYP1A2TNKS | |
| SCHEMBL17786634 | 0.79 | GUSB (0.58) | GUSBCYP1A1CYP1B1CYP1A2TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8158637-B2 | Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-17 | — | — | US | disclosed |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-09-28 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-09 | — | — | US | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | GUSB 3959/4885CYP1A1 3297/4885CYP1B1 3679/4885 |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | GUSB 4306/4885CYP1A1 3259/4885CYP1B1 3757/4885 |
| US-20080167305-A1 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | KCNQ1, KCNQ2, KCNQ5 | GUSB 3983/4885CYP1A1 3067/4885CYP1B1 3419/4885 |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | GUSB 4306/4885CYP1A1 3259/4885CYP1B1 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.